Regulation of prostaglandin production in intact fetal membranes by interleukin-1 and its receptor antagonist

N L Brown, S A Alvi, M G Elder, P R Bennett and M H F Sullivan

Department of Maternal and Fetal Medicine, Division of Paediatrics, Obstetrics and Gynaecology, Imperial College School of Medicine, Queen Charlotte's and Chelsea Hospital, Goldhawk Road, London W6 0XG, UK

(Requests for offprints should be addressed to M H F Sullivan)

Abstract

There is strong evidence for the involvement of inflammatory mediators such as interleukin (IL)-1 in the biochemical mechanisms of parturition. Therefore the effects of the IL-1 family (IL-1 α (1 ng/ml), IL-1 β (1 ng/ml) and the IL-1 receptor antagonist (IL-1ra) (10 ng/ml)) on the regulation of prostaglandin synthesis in term human fetal membranes were investigated. It was found that, after 4 h of culture, IL-1 β increased prostaglandin E₂ (PGE₂) output approximately twofold. This was associated with both a significant increase in cyclo-oxygenase-2 (COX-2) mRNA levels (approximately fourfold compared with control) and translocation of cytoplasmic phospholipase A₂ (cPLA₂) from the cytosol to the membrane fraction. IL-1 α was less effective than IL-1 β at stimulating PGE₂ production through similar mechanisms.

IL-1ra had no effect on PGE₂ output. However, in combination treatments, IL-1ra did not inhibit IL-1 α - or IL-1 β -stimulated PGE₂ output, and increased PGE₂ production further compared with IL-1 β alone. IL-1ra decreased IL-1 β -induced COX-2 mRNA expression by about half and significantly increased cPLA₂ protein levels, as detected by immunoblotting, when used alone and together with IL-1 β . These results suggest that IL-1ra has partial agonist properties when used together with IL-1 α and IL-1 β in fetal membranes by increasing cPLA₂ protein levels, which leads to an increase in the production of prostaglandins.

Journal of Endocrinology (1998) **159**, 519–526

Introduction

The biochemical signals that initiate human parturition are not completely understood. There is good evidence for prostaglandins, in particular PGE₂ and PGF_{2 α} , being important mediators in the onset of human labour by inducing myometrial contractions (Carraher *et al.* 1983), ripening of the cervix (Ellwood *et al.* 1980) and membrane rupture (Challis & Olson 1988). Prostaglandins are produced by the amnion, chorion, decidua, myometrium and placenta (Duchesne *et al.* 1978, Olson & Zakar 1993). The precise regulatory mechanisms responsible for their increase at term have not been fully resolved. Many factors can increase prostaglandin production, including cytokines (Mitchell *et al.* 1991, 1993a, Norwitz *et al.* 1992, Ishihara *et al.* 1996) and growth factors (Kniss *et al.* 1992).

The first step in the synthesis of prostaglandins is the hydrolysis of arachidonic acid from cell membrane phospholipids, predominantly by the action of phospholipase A₂ (PLA₂). There are multiple forms of PLA₂ which include the cytosolic group IV (cPLA₂) (Clark *et al.* 1991), the secretory group (sPLA₂) (Seilhamer *et al.* 1989) and a cytosolic Ca²⁺-independent PLA₂ (iPLA₂) (Buhl *et al.* 1995). The free arachidonic acid can then be

converted to the intermediates PGG₂ and PGH₂ by the action of prostaglandin H synthase (alternatively known as cyclo-oxygenase (COX)), and can then be further metabolised to prostaglandins, prostacyclin or thromboxanes. There are two isoforms of COX which are encoded by different genes (Hla *et al.* 1986, Hla & Neilson 1992, Takahashi *et al.* 1992): COX-1, which is constitutively expressed, and COX-2, which can be upregulated in response to stimuli such as cytokines and growth factors (Mitchell *et al.* 1993a, Albert *et al.* 1994, Angel *et al.* 1994).

Fetal membrane PLA₂ activity increases throughout gestation (Schultz *et al.* 1975), and total cellular cPLA₂ has also been found to be high before the onset of labour in the amnion and depleted after delivery (Skannal *et al.* 1997). It has also been shown that IL-1 β can rapidly induce cPLA₂ protein expression and activity with a parallel increase in PGE₂ synthesis in amnion-derived WISH cells, and that this can be inhibited using a cPLA₂-specific inhibitor (Xue *et al.* 1995).

There is evidence for increased amnion COX enzyme activity in association with the onset of labour at term (Smieja *et al.* 1993, Teixeira *et al.* 1994) and mRNA expression of COX-2 with the onset of labour (Slater

et al. 1995, Hirst *et al.* 1995). Interleukin (IL)-1 β has also been reported to increase prostaglandin synthesis in both amnion primary cells and WISH cells by induction of COX-2 mRNA and protein (Mitchell *et al.* 1993a, Albert *et al.* 1994).

IL-1 is a proinflammatory cytokine which exists in two biochemically related but distinct forms known as IL-1 α and IL-1 β . The third member of the family is the receptor antagonist (IL-1ra) which is generally thought to compete with IL-1 α and IL-1 β for the cell surface receptor without initiating signal transduction (Arend 1991). There are two types of IL-1 receptor (Sims *et al.* 1989, McMahan *et al.* 1991) but only the type 1 receptor (IL-1 R1) has been shown to transduce the IL-1 signal (Sims *et al.* 1993). IL-1 β is found in increased levels in the amniotic fluid of women in preterm labour associated with infection (Romero *et al.* 1989) as well as spontaneous labour at term (Romero *et al.* 1990). IL-1ra has been found to prevent IL-1-induced preterm labour in mice (Romero & Tartakovsky 1992), but other workers have reported that, in cultured human decidual cells, IL-1ra can act as a partial agonist of prostaglandin production (Cole *et al.* 1993, Mitchell *et al.* 1993b).

In this study, we have used an intact fetal membrane culture system to investigate how the IL-1 family regulates prostaglandin synthesis and how their effects are modulated by the receptor antagonist.

Materials and Methods

Tissue collection and culture

Fetal membranes were collected from uncomplicated pregnancies at term (38–40 weeks gestation) after elective caesarean section in the absence of labour and infection. Patients had not taken any anti-inflammatory drugs for 2 weeks before delivery and were not suffering from pre-eclampsia. Ethics committee approval was obtained to use tissues that would normally be discarded. Tissue was washed with PBS containing 10% penicillin, streptomycin and L-glutamine (Sigma, Poole, Dorset, UK). Disks of intact tissue were cut using a sharpened punch and cultured in Medium 199 supplemented with ITS (insulin, transferrin, selenium and linoleic acid, all at 0.63 mg/ml, and BSA at 0.13 mg/ml; Sigma) in multiwell tissue culture plates for 24 h at 37 °C in an atmosphere of 5% CO₂/95% air. The medium was also supplemented with 1 mM aspirin, as we have shown that fetal membranes may be preactivated and spontaneously release high levels of PGE₂ (Brown *et al.* 1998). After this time the medium was changed, the tissue washed with medium containing no aspirin, and incubated with or without IL-1 α , IL-1 β or IL-1ra or combinations of these for time periods stated in the Results section. The tissues were snap-frozen in liquid nitrogen and stored at –80 °C. The supernatants

were then removed and frozen at –20 °C until analysis for PGE₂ levels by ELISA (Amersham International, Amersham, Bucks, UK). PGE₂ levels were then expressed as a fold change relative to the control levels.

RNA extraction and reverse transcriptase (RT)-PCR

Total RNA was extracted using a standard guanidinium isothiocyanate technique (Chomczynski & Sacchi 1987) and stored at –80 °C until use. RNA samples (1 μ g) were denatured at 70 °C for 5 min and cooled to 37 °C. Reverse transcription was carried out using $\times$ 1 first-strand buffer (Gibco, New York, NY, USA), 0.25 μ g random hexanucleotide primers (Pharmacia, Uppsala, Sweden), 10 mM dithiothreitol, 1 mM each deoxynucleotide triphosphate (dNTP; Gibco), 1 U RNase inhibitor (Pharmacia) and 40 U Moloney murine leukaemia virus reverse transcriptase (Gibco) for 60 min at 37 °C in a reaction volume of 20 μ l. The reaction was stopped by incubation at 90 °C for 4 min, and the resultant cDNA stored at –80 °C until PCR amplification.

The COX-1 and COX-2 primers for PCR have been previously reported (Slater *et al.* 1995). The other primers used were: cPLA₂, 5'-GAG CTG ATG TTT GCA GAT TGG GTT-3' (sense) and 5'-GTC ACT CAA AGG AGA CAG TGG ATA AGA-3' (antisense); and sPLA₂, 5'-GCT GTG TCA CTC ATG ACT GTT-3' (sense) and 5'-GGA GTA CAG CTT CTT TGG TTA-3' (antisense). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers have been described previously (Tso *et al.* 1985). PCR was performed in a volume of 25 μ l containing 1:20 volume of the cDNA, 1 $\times$ NH₄ buffer (Bioline, London, UK), 1.5 mM MgCl₂, 0.2 mM dNTP, 125 ng each sense and antisense primer and 0.5 U *Taq* polymerase (Bioline). After an initial denaturation step of 2 min at 94 °C, target cDNA was amplified by denaturing at 94 °C for 30 s, primer annealing (58 °C for GAPDH and COX-2; 55 °C for sPLA₂ and cPLA₂) for 30 s and primer extension at 72 °C for 30 s. Cycle profiles were performed as described previously to ensure that the exponential phase was used to amplify the products (Slater *et al.* 1995). Aliquots of the PCR products were separated by agarose gel electrophoresis and visualised under UV light.

To quantify the PCR results, 5 μ l of each PCR mixture was dotted on to Hybond nylon filters. The filters were first washed in denaturing solution (1.5 M NaCl, 0.5 M NaOH), neutralised (1.5 M NaCl, 0.5 M Tris-HCl, pH 7.5) and lastly washed in 3 $\times$ sodium citrate buffer (20 $\times$ SSC: 0.3 M NaCl, 0.3 M sodium citrate, pH 7.0) for 5 min each. The DNA was fixed to the filters by UV crosslinking. Filters were first prehybridised for 1–2 h at 65 °C followed by hybridisation overnight with the appropriate [³²P]dCTP-labelled cDNA probe at 65 °C. Excess probe was removed by washing in a series of SSC buffer washes containing 0.1% SDS from 3 $\times$ SSC down

to $0.1 \times \text{SSC}$. The levels of cDNA were then determined by β -counting of the filter sections. Expression of each product was then calculated as a ratio relative to the expression of GAPDH. The ratios were then represented as a fold increase or decrease in mRNA expression.

Immunoblot analysis for protein phosphorylation of cPLA₂

Fetal membrane disks were allowed to thaw in 0.5 ml homogenisation buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA and 1 mM sodium orthovanadate) containing the protease inhibitors pepstatin A (1 μM), phenylmethylsulphonyl fluoride (0.1 mM) and E-64 (*trans*-epoxysuccinyl-L-leucylamido-(4-guanidino)butane) (10 μM). Tissue was homogenised in short bursts on ice and the total lysate was then centrifuged for 10 min at 13 000 *g* to pellet cell debris. Protein levels were determined by Bradford assay using BSA as the standard, and 200 μg of each sample was loaded on an SDS-12% polyacrylamide gel. To demonstrate a phosphorylation-stimulated shift in cPLA₂ mobility (Lin *et al.* 1992a, Croxtall *et al.* 1996), the separating gel was made using an acrylamide:bisacrylamide ratio of 30:0.5. To improve the resolution of the protein bands, 67 mM imidazole was included in both the stacking gel and the sample buffer (Rittenhouse & Marcus 1984). Purified cPLA₂ (Genetics Institute, Cambridge, MA, USA) was also included on each gel as a positive control. The gels were run overnight until the 29 kDa molecular mass marker had run to the bottom of the gel. The proteins were then electrophoretically transferred to a nitrocellulose filter at 350 mA for 4 h in transfer buffer containing 16.5 mM Tris, 191 mM glycine and 20% methanol. The filter was blocked in PBS containing 0.1% Tween and 5% non-fat milk for 2 h at room temperature. cPLA₂ protein was detected by incubation of the filter overnight at 4 °C with a rabbit polyclonal antibody (Santa Cruz, Biotechnology Inc., Santa Cruz, CA, USA) which was diluted 1:500 in PBS-0.1% Tween containing 1% non-fat milk. This was followed by a 1 h incubation with an anti-rabbit IgG antibody labelled with peroxidase (Sigma). Immunolocalised proteins were then detected using a chemiluminescent detection system (ECL; Amersham International). The filters were also incubated with a β -actin goat polyclonal antibody (Santa Cruz) (1:2000 dilution) and then an anti-goat peroxidase-labelled antibody (Santa Cruz) (1:1000 dilution) to verify equal loading of the samples. The filters were stripped using stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) and incubated at 50 °C for 30 min with occasional agitation. The filter was then washed in PBS-0.1% Tween, blocked as before and incubated with either a COX-1 or COX-2 goat polyclonal antibody (Santa Cruz) (1:500 dilution). Human platelets were used as a

Figure 1 PGE₂ output from fetal membranes after incubation with members of the IL-1 family for 4 h. Concentrations used were 1 ng/ml for IL-1 β and IL-1 α , and 10 ng/ml for IL-1ra. PGE₂ output is expressed as a fold increase compared with the control. Results shown are mean $\pm$ S.E.M. for at least five experiments in which each treatment was performed in triplicate. *Statistically significant difference ($P < 0.05$).

positive control for COX-1, and, for COX-2, lymphocytes stimulated with lipopolysaccharide were used.

Immunoblot detection of cPLA₂ translocation from the cytosol to the membrane

Fetal membrane disks were homogenised in 0.5 ml translocation buffer (25 mM Hepes, pH 7.4, 5 mM EDTA, 50 mM NaF and 1 mM sodium orthovanadate). The total lysate was then spun for 10 min at 4 °C at 13 000 *g*, and the resulting cytosol spun at 100 000 *g* for 1 h at 4 °C. This gave cytosolic (supernatant) and membrane (pellet) fractions. The membrane pellet was resuspended in 40 μl translocation buffer. Then 100 μg of the cytosolic fractions and each membrane fraction were loaded on an SDS-12% polyacrylamide gel. The proteins were electroblotted, and cPLA₂ and β -actin were immunodetected as described above.

Analysis of immunoblots

The autoradiographs of each blot were scanned by a UMAX Mirage D-16L scanner and the integrated density

Figure 2 Changes in COX-2 protein levels after treatment with IL-1β, IL-1α or IL-1ra or combinations of these treatments for 4 h: (A) typical immunoblot; (B) histogrammic summary of three such immunoblots analysed by densitometry showing the mean $\pm$ S.E.M. COX-2 levels in each sample were corrected for β -actin concentration and then expressed as fold change compared with the control level. *Statistically significant difference ($P < 0.05$).

of each band determined using the software package Whole Band Analyser (Genomic Solutions Ltd, Eaton Socon, Cambs., UK). The integrated density for cPLA₂ or COX was then expressed relative to the density of β -actin for each sample.

Statistical analysis

The results are shown as mean $\pm$ S.E.M. For statistical analysis, the results were log-transformed and investigated by ANOVA with post-hoc analysis by Fisher's exact test. Significance was set at $P < 0.05$.

Results

We determined the optimum concentration of IL-1β and IL-1α for stimulating PGE₂ production to be 1 ng/ml, and that for IL-1ra was 10 ng/ml. IL-1β significantly increased

Figure 3 Changes in the expression of COX-2 transcript after treatment with IL-1β, IL-1α or IL-1ra or combinations of these treatments for 4 h. The COX-2 mRNA levels in each sample were calculated relative to GAPDH and then expressed as fold change compared with the control. The results are mean $\pm$ S.E.M. for three experiments in which each treatment was performed in triplicate. *Statistically significant difference ($P < 0.05$).

PGE₂ output from fetal membranes over twofold compared with control levels after 4 h of treatment, whereas IL-1α was less potent (Fig. 1). IL-1ra alone did not increase prostaglandin release. When IL-1β and IL-1ra were incubated together, PGE₂ production was increased more than with IL-1β alone. The combination of IL-1α and IL-1ra caused the same increase in PGE₂ output as IL-1α alone.

A similar pattern was found when the levels of COX-2 protein were investigated by immunoblotting (Fig. 2). There was a significant increase with IL-1β plus IL-1ra and also with IL-1ra treatment on its own. Treatment with IL-1α or IL-1α plus IL-1ra did not significantly increase the levels of COX-2 protein. Immunoblots were also performed for the COX-1 isoform. However, only very low levels of COX-1 could be detected which were not affected by any of the treatments (results not shown).

Expression of COX-1 and COX-2 mRNA was investigated using RT-PCR. COX-1 cDNA was detected in very low amounts using high cycle numbers (data not shown). As expected, COX-2 was highly abundant in fetal membranes incubated with IL-1β, a significant fourfold increase in mRNA levels over those in controls being observed after 4 h of treatment (Fig. 3). Once again, IL-1α

Figure 4 Changes in the expression of cPLA₂ mRNA following treatment for 4 h with IL-1β, IL-1α or IL-1ra or combinations of these treatments. The levels of cPLA₂ in each sample were expressed relative to GAPDH and then expressed as a fold change compared with the control. The results are mean ± S.E.M. for three experiments and each treatment was performed in triplicate.

was less potent, with a trend towards an increase in COX-2 mRNA expression that was not significant. IL-1ra did not increase COX-2 mRNA expression and reduced IL-1β-upregulated COX-2 mRNA by half.

Expression of cPLA₂ mRNA after 4 h of treatment was investigated by RT-PCR (Fig. 4). This was found to be abundant but no significant changes were found with any of the treatment groups relative to control levels. Longer treatments with IL-1β for time periods of up to 72 h similarly did not result in an increase in cPLA₂ mRNA expression (data not shown). Expression of sPLA₂ mRNA was also investigated; only very low levels could be detected after high PCR cycle numbers (data not shown).

Phosphorylation of cPLA₂ reduces its electrophoretic mobility, which offers a convenient way of following agonist-induced changes in the phosphorylated state. Possible changes in the phosphorylated state of cPLA₂ after the various treatments were therefore investigated (Fig. 5). IL-1β, IL-1α, IL-1ra and IL-1β plus IL-1ra treatment all significantly increased the amount of phosphorylated protein but did not change the ratio of the phosphorylated to unphosphorylated form.

Translocation of cPLA₂ from the cytosol to the endoplasmic reticulum (ER) and nuclear membranes after 2 h of each of the different treatments was also investigated (Fig. 6A–C). IL-1β and IL-1α produced a significant

Figure 5 (A) Immunoblot showing the phosphorylation status of cPLA₂ after treatment with IL-1β or IL-1ra. P-cPLA₂, phosphorylated enzyme; DeP-cPLA₂, unphosphorylated form of the enzyme. (B) Analysis of three immunoblots by densitometry showing the integrated density (mean ± S.E.M.). The cPLA₂ levels in each sample were corrected for the integrated density of β-actin and then expressed as fold change compared with the control. *Statistically significant difference ($P < 0.05$).

increase in cPLA₂ translocation from the cytosol to the membrane. Treatment with IL-1ra alone and IL-1β plus IL-1ra resulted in an approximately equal distribution between the cytosol and membrane and an overall significant increase in the total mass of cPLA₂ (Fig. 6D).

Discussion

This study examined the mechanisms by which IL-1α, IL-1β and IL-1ra regulate prostaglandin biosynthesis in intact fetal membranes collected at term. The tissue explants used consisted of adherent amnion, chorion and decidua, which is a better representation of *in vivo* conditions than isolated cell types. IL-1β was found to be a potent stimulator of PGE₂ production from intact fetal membranes, which is consistent with studies performed using amnion and decidual cells (Mitchell *et al.* 1993a, Albert *et al.* 1994, Cole *et al.* 1995, Kennard *et al.* 1995,

Figure 6 (A) Immunoblot of cytosolic and membrane fractions following treatment with IL-1β or IL-1ra. Lane 1 is a cPLA₂ positive control. (B) Immunoblot of cytosolic and membrane fractions following treatment with IL-1α or IL-1ra. (C) Analysis of three immunoblots by densitometry showing the percentage distribution of total cPLA₂ in either the cytosolic or membrane fractions after 2 h of each of the treatments. (D) Change in total cPLA₂ levels (combining those found in the cytosolic and membrane fractions). Results shown are the integrated density (mean ± S.E.M.) where cPLA₂ levels were corrected for β-actin concentration and expressed as fold change compared with the control. *Statistically significant difference ($P < 0.05$).

Xue *et al.* 1995). This increase in PGE₂ production was associated with a large increase in COX-2 mRNA expression (Fig. 3). The increase in COX-2 protein was less dramatic than that of COX-2 mRNA (Fig. 2). This is probably due to the instability of COX-2 protein, which has a half-life of approximately 30 min (DeWitte & Meade 1993, Evett *et al.* 1993). COX-2 mRNA is also unstable (DeWitte & Meade 1993), and IL-1β may cause upregulation of its expression to compensate for this. IL-1ra reduced IL-1β-stimulated COX-2 mRNA expression by half, which almost reached significance ($P = 0.083$), suggesting that it antagonises the effects of IL-1β at the mRNA level. Other workers have found that IL-1ra suppressed IL-1α-driven prostaglandin synthesis in human endometrial cells by inhibiting the induction of COX-2 mRNA and protein (Kniss *et al.* 1997). This group also found that when endometrial cells were incubated with IL-1ra at a dose of 10 ng/ml, prostaglandin production was significantly higher than the control, suggesting that IL-1ra may have partial agonist-like properties.

cPLA₂ is selective for phospholipids with arachidonic acid in the *sn*-2 position and has been shown to be coupled

to the hormonal release of arachidonic acid (Lin *et al.* 1992a), and the accumulation of cPLA₂ has been reported after IL-1 treatment (Lin *et al.* 1992b, Angel *et al.* 1994, Xue *et al.* 1995). It is therefore probably involved in receptor-mediated eicosanoid production. Two mechanisms are involved in the activation of cPLA₂: it may be post-translationally modified by phosphorylation, which increases enzyme activity, and this is followed by Ca²⁺-dependent translocation to the ER and nuclear membranes.

None of the IL-1 family was found to change the expression of cPLA₂ transcript in the time period studied. Longer incubations with IL-1β of up to 72 h were also performed but no increases in cPLA₂ mRNA were found. Therefore post-transcriptional changes in cPLA₂ may be responsible for the increases in PGE₂ production found. In our study of the activation of cPLA₂ by phosphorylation and Ca²⁺-mediated translocation to the nuclear envelope and/or ER, increased levels of the phosphorylated form of cPLA₂ were found after treatment with IL-1β, IL-1α, IL-1ra and IL-1β plus IL-1ra. This was a result of increased cPLA₂ protein mass rather than a change in the ratio of phosphorylated to unphosphorylated protein and

therefore a higher level of active protein compared with the control. This induction by IL-1 β of cPLA₂ protein levels without a change in the phosphorylation status of the enzyme has also been reported in amnion-derived WISH cells (Honican *et al.* 1998).

IL-1 β increased translocation of cPLA₂ to the membrane compared with the control. As Ca²⁺ appears to be essential for cPLA₂ activation, IL-1 may stimulate the production of a Ca²⁺-mobilising agent (Ikeda *et al.* 1990). Translocation was inhibited by IL-1ra, with equal distribution in the cytosol and membrane fractions. However, IL-1ra treatment did lead to an increase in cPLA₂ mass compared with treatment with IL-1 β alone. This may be the mechanism by which IL-1ra enhances the effect of IL-1 β , i.e. it increases cPLA₂ mass which can then mobilise more substrate to be metabolised by COX to give PGE₂.

Unfortunately, the assay used for cPLA₂, which measured the release of radiolabelled arachidonic acid from arachidonyl-containing phospholipid, was not sensitive enough to give accurate measurements in the tissue explants.

COX-1 and sPLA₂ transcripts were virtually undetectable after treatment with IL-1 β , IL-1 α or IL-1ra and are therefore probably not involved in their regulatory mechanism. A similar finding has been reported for the treatment of human synovial cells with IL-1 (Angel *et al.* 1994).

In conclusion, IL-1 β activates PGE₂ output from fetal membranes by upregulating COX-2 gene expression and increasing the translocation of cPLA₂ from the cytosol to the cellular membranes. IL-1 α is a less potent activator of PGE₂ output by similar mechanisms. A very important finding was that IL-1ra can upregulate PGE₂ production from IL-1 β -stimulated fetal membrane explants, and this appeared to be as a result of increasing cPLA₂ protein levels. As the transcript levels do not change, it suggests that IL-1ra may stabilise either the mRNA or the protein. It has been postulated that IL-1ra may bind to the decoy type II IL-1 receptor, thereby dislodging any bound IL-1, which could then in turn bind to the type I receptor (Kniss *et al.* 1997). However, the results of our study suggest that IL-1ra has different effects on the prostaglandin pathway than those of IL-1 β : it acts on cPLA₂ protein levels, whereas IL-1 β acts primarily by upregulating COX-2. IL-1ra has been found to block IL-1-induced prostaglandin production by amnion and chorion primary cells (Romero *et al.* 1992b) and so it would be appear that IL-1ra has a unique role in the decidua. The signal transduction pathway by which IL-1ra achieves this effect is beyond the scope of this paper and needs to be addressed in future work.

Acknowledgements

We would like to thank Action Research (NLB) and WellBeing (SAA) for supporting this work. We would also

like to thank the Genetics Institute Inc, MA, USA for supplying us with a sample of pure cPLA₂ protein. We also gratefully acknowledge Dr Steve Dilworth for allowing us to use his image scanner and the Bioimage Whole Band Analyser software.

References

- Albert TJ, Su H-C, Zimmerman PD, Iams JD & Kniss DA 1994 Interleukin-1 β regulates the inducible cyclooxygenase in amnion-derived wish cells. *Prostaglandins* **48** 401–416.
- Angel J, Berenbaum F, Le Denmat C, Nevalainen T, Masliah J & Fournier C 1994 Interleukin-1-induced prostaglandin E₂ biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A₂ and cyclooxygenase-2. *European Journal of Biochemistry* **226** 125–131.
- Arend WP 1991 Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. *Journal of Clinical Investigation* **88** 1445–1451.
- Brown NL, Alvi SA, Elder MG, Bennett PR & Sullivan MHF 1998 A spontaneous induction of fetal membrane prostaglandin production precedes clinical labour. *Journal of Endocrinology* **157** R1–R6.
- Buhl W-J, Eisenlohr LM, Preuss I & Gehring U 1995 A novel phospholipase A₂ from human placenta. *Biochemical Journal* **311** 147–153.
- Carraher R, Hahn DW, Ritchie DM & McGuire JL 1983 Involvement of lipoxygenase products in myometrial contractions. *Prostaglandins* **26** 23–32.
- Challis JRG & Olson DM 1988 Parturition. In *The Physiology of Reproduction*, p 2177. Eds E Knobil & J Neill. New York: Raven Press.
- Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by guanidinium thiocyanate–phenol–chloroform extraction. *Analytical Biochemistry* **162** 156–159.
- Clark JD, Lin L-L, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N & Knopf JL 1991 A novel arachidonic acid-selective cytosolic PLA₂ contains a Ca²⁺-dependent translocation domain with homology to PKC and GAP. *Cell* **65** 1043–1051.
- Cole OF, Sullivan MHF & Elder MG 1993 The interleukin-1 receptor antagonist is a partial agonist of prostaglandin synthesis by human decidua cells. *Prostaglandins* **46** 493–498.
- Cole OF, Seki H, Elder MG & Sullivan MHF 1995 Interleukin-1 β independently stimulates production of prostaglandin E₂ and cyclic AMP from human decidua cells. *Biochimica et Biophysica Acta* **1269** 139–144.
- Croxtall JD, Choudhury Q, Newman S & Flower RJ 1996 Lipocortin 1 and the control of cPLA₂ activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA₂ phosphorylation. *Biochemical Pharmacology* **52** 351–356.
- DeWitte DL & Meade EA 1993 Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. *Archives of Biochemistry and Biophysics* **306** 94–102.
- Duchesne MJ, Thaler-Dao H & Crastes de Paulet A 1978 Prostaglandin synthesis in human placenta and fetal membranes. *Prostaglandins* **15** 19–42.
- Ellwood DA, Mitchell MD & Anderson ABM 1980 The *in vitro* production of prostanoids by the human cervix during pregnancy: preliminary observations. *British Journal of Obstetrics and Gynaecology* **87** 210–214.
- Evvett GE, Xie W, Chipman JE, Robertson DL & Simmons DL 1993 Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. *Archives of Biochemistry and Biophysics* **306** 169–177.

- Hirst JJ, Teixeira FJ, Zakar T & Olson DM 1995 Prostaglandin-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset. *Journal of Clinical Endocrinology and Metabolism* **80** 517–523.
- Hla T & Neilson K 1992 Human cyclo-oxygenase-2 cDNA. *Proceedings of the National Academy of Sciences of the USA* **89** 7384–7388.
- Hla T, Farrell M, Kumar A & Bailey JM 1986 Isolation of the cDNA for human prostaglandin H synthase. *Prostaglandins* **32** 829–845.
- Honican D, Brockman DE & Myatt L 1998 Transcriptional and post-translational regulation of cytosolic phospholipase A₂ by IL-1 and EGF in WISH cells. *Journal of the Society for Gynecologic Investigation* **5** 59A (Abstract no. 81).
- Ikeda U, Ikeda M, Oohara T, Kano S & Yaginuma T 1990 Mitogenic action of interleukin-1 alpha on vascular smooth muscle cells mediated by PDGF. *Atherosclerosis* **84** 183–188.
- Ishihara O, Numari H, Saitoh M, Arai Y, Takanashi H, Kitagawa H & Kinoshita K 1996 Prostaglandin E₂ production by endogenous secretion of interleukin-1 in decidual cells obtained before and after the labor. *Prostaglandins* **52** 199–208.
- Kennard EA, Zimmerman PD, Friedman CI & Kniss DA 1995 Interleukin-1 beta induces cyclooxygenase-2 in cultured human decidual cells. *American Journal of Reproductive Immunology* **34** 65–71.
- Kniss DA, Zimmerman PD, Fertel RH & Iams JD 1992 Proinflammatory cytokines interact synergistically with epidermal growth factor to stimulate PGE₂ production in amnion-derived cells. *Prostaglandins* **44** 237–244.
- Kniss DA, Zimmerman PD, Garver CL & Fertel RH 1997 Interleukin-1 receptor antagonist blocks interleukin-1-induced expression of cyclooxygenase in endometrium. *American Journal of Obstetrics and Gynecology* **177** 559–567.
- Lin L-L, Lin AY & Knopf JL 1992a Cytosolic phospholipase A₂ is coupled to hormonally regulated release of arachidonic acid. *Proceedings of the National Academy of Sciences of the USA* **89** 6147–6151.
- Lin L-L, Lin AY & DeWitt DL 1992b Interleukin-1α induces the accumulation of cytosolic phospholipase A₂ and the release of prostaglandin E₂ in human fibroblasts. *Journal of Biological Chemistry* **267** 23451–23454.
- McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, Brannan CI, Copeland NG, Huebner K, Croce CM, Cannizzaro LA, Benjamin D, Dower SK, Spriggs MK & Sims JE 1991 A novel IL-1 receptor cloned from B cells by mammalian expression is expressed in many cell types. *EMBO Journal* **10** 2821–2832.
- Mitchell MD, Dudley DJ, Edwin SS & Schiller SL 1991 Interleukin-6 stimulates prostaglandin production by human amnion and decidual cells. *European Journal of Pharmacology* **192** 189–191.
- Mitchell MD, Edwin SS, Lundin-Schiller S, Silver RM, Smotkin D & Trautman MS 1993a Mechanism of interleukin-1 beta stimulation of human amnion prostaglandin biosynthesis: mediation via a novel inducible cyclooxygenase. *Placenta* **14** 615–625.
- Mitchell MD, Edwin S, Silver RM & Romero RJ 1993b Potential agonist action of the interleukin-1 receptor antagonist: implications for treatment of women. *Journal of Clinical Endocrinology and Metabolism* **76** 1386–1388.
- Norwitz ER, Lopez Bernal A & Starkey PM 1992 Tumor necrosis factor-α selectively stimulates prostaglandin F_{2α} production by macrophages in human term decidua. *American Journal of Obstetrics and Gynecology* **167** 815–820.
- Olson DM & Zakar T 1993 Intrauterine tissue prostaglandin synthesis: regulatory mechanisms. *Seminars in Reproductive Endocrinology* **11** 234.
- Rittenhouse J & Marcus F 1984 Peptide mapping by polyacrylamide gel electrophoresis after cleavage at aspartyl-prolyl peptide bonds in sodium dodecyl sulfate-containing buffers. *Analytical Biochemistry* **138** 442–448.
- Romero R & Tartakovsky B 1992 The natural interleukin-1 receptor antagonist prevents interleukin-1 induced preterm delivery in mice. *American Journal of Obstetrics and Gynecology* **167** 1041–1045.
- Romero R, Brody DT, Oyarzun E, Mazor M & Wu YK 1989 Infection and labour. III. Interleukin-1: a signal for the onset of parturition. *American Journal of Obstetrics and Gynecology* **160** 1117–1123.
- Romero R, Parvizi ST, Oyarzun E, Mazor M, Wu YK, Avila C, Athanassiadis A & Mitchell MD 1990 Amniotic fluid interleukin-1 in spontaneous labor at term. *Journal of Reproductive Medicine* **35** 235–238.
- Romero RJ, Sepulveda W, Mazor M, Brandt F, Cotton DB, Dinarello CA & Mitchell MD 1992 The natural interleukin-1 receptor antagonist in human amniotic fluid in term and preterm parturition. *American Journal of Obstetrics and Gynecology* **167** 863–872.
- Schultz BE, Schwarz BE, MacDonald PC & Johnston JM 1975 Initiation of human parturition. IV. Demonstration of phospholipase A₂ in fetal chorioamnion and uterine decidua. *American Journal of Obstetrics and Gynecology* **123** 650–653.
- Seilhamer J, Pruzanski W, Vadas P, Plant S, Miller J, Kloss J & Johnson L 1989 Cloning and recombinant expression of phospholipase A₂ present in rheumatoid arthritic synovial fluid. *Journal of Biological Chemistry* **264** 5335–5338.
- Sims JE, Acres RB, Grubin CE, McMahan CJ, Wignall JM, March CJ & Dower SK 1989 Cloning of the interleukin 1 receptor from human T cells. *Proceedings of the National Academy of Sciences of the USA* **86** 8946–8950.
- Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani AM, Shanebeck K, Grabstein KH & Dower SK (1993) Interleukin 1 signaling occurs exclusively via the type 1 receptor. *Proceedings of the National Academy of Sciences of the USA* **90** 6155–6159.
- Skannal DG, Brockman DE, Eis ALW, Xue S, Siddiqi TA & Myatt L 1997 Changes in activity of cytosolic phospholipase A₂ in human amnion at parturition. *American Journal of Obstetrics and Gynecology* **177** 179–184.
- Slater DM, Berger LC, Newton R, Moore GE & Bennett PR 1995 Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. *American Journal of Obstetrics and Gynecology* **172** 77–82.
- Smieja Z, Zakar T, Walton J & Olson DM 1993 Prostaglandin endoperoxide synthase kinetics in human amnion before and after labor at term and following preterm labor. *Placenta* **14** 163–175.
- Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A & Shibata A 1992 Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclo-oxygenase). *Biochemical and Biophysical Research Communications* **182** 433–438.
- Teixeira FJ, Zakar T, Hirst JJ, Guo F, Sadowsky DW, Machin G, Demianczuk N, Resch B & Olson DM 1994 Prostaglandin endoperoxide-H synthase (PGHS) activity and immunoreactive PGHS-1 and PGHS-2 levels in human throughout gestation, at term, and during labor. *Journal of Clinical Endocrinology and Metabolism* **78** 1396–1402.
- Tso JY, Sun XH, Kao TH, Reece KS & Wu R 1985 Isolation and characterisation of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. *Nucleic Acids Research* **13** 2485–2502.
- Xue S, Brockman DE, Slater DM & Myatt L 1995 Interleukin-1β induces the synthesis and activity of cytosolic phospholipase A₂ and the release of prostaglandin E₂ in human amnion-derived WISH cells. *Prostaglandins* **49** 351–369.

Received 18 May 1998
Accepted 19 August 1998